The suspension of a Phase IIb trial of Bristol-Myers Squibb's BMS-986094 nucleotide polymerase inhibitor resulted in a $1.8 billion write-off. Other expensive failures include a joint Pfizer-Johnson & Johnson candidate for Alzheimer's disease, an AstraZeneca and Targacept adjunct to antidepressant treatment, and an Eli Lilly & Co. schizophrenia drug.
Drugmakers took big hits last year on failed clinical trials
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||